Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir

Trial Profile

Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Most Recent Events

    • 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 30 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top